Interpreting blood–brain barrier bypass claims in reperfused stroke: a minimum reporting framework for intracalvarial immune-assisted nanoparticle delivery
By
Dandan Liu
Hezhong Ouyang
Xiaojin Wei
Zhengwei Chen
Shiyao Zhang
Fuling Yan
June 19, 2026
Clinical Scorecard: Evaluating Claims of Blood-Brain Barrier Disruption in Reperfused Stroke: A Reporting Framework for Immune-Enhanced Nanoparticle Delivery within the Skull
At a Glance
Category Detail
Condition Reperfused Stroke Key Mechanisms Skull-assisted immune transport, injury-enabled access, lesion-driven immune recruitment Target Population Patients experiencing reperfused stroke Care Setting Clinical research and experimental studies
Key Highlights
Intracalvarial delivery engages local immune-cell populations for CNS drug delivery. BBB integrity changes during reperfusion complicate interpretations of nanoparticle signals. A minimum reporting framework is proposed to clarify BBB-bypass claims. Guideline-Based Recommendations
Diagnosis
Assess BBB integrity at time points aligned with dosing and sampling. Management
Differentiate between skull-assisted immune transport and injury-enabled access. Monitoring & Follow-up
Report compartment-resolved localization of signals in post-stroke studies. Risks
Overinterpretation of BBB bypass without clear mechanistic evidence. Patient & Prescribing Data
Patients with ischemia-reperfusion injury in stroke.
Nanoparticle delivery may enhance therapeutic outcomes but requires careful evidence assessment.
Clinical Best Practices
Align timing of ischemia onset, reperfusion, dosing, and BBB assessment. Use controls to distinguish between vascular and extravascular signals. Employ imaging techniques to clarify the localization of nanoparticle signals. Related Resources & Content
